Follistatin is a secreted glycoprotein studied in research as a ligand trap within the TGF-β superfamily. Rather than acting at a receptor itself, it binds activin, GDF-8 (myostatin), and some bone morphogenetic proteins directly, which keeps those ligands from engaging their receptor complexes. In the Amino Kinetics catalog, Follistatin is listed under CAS number 117628-82-7. The catalog gives its molecular weight as approximately 37,000 to 40,000 Da for the recombinant form and approximately 3780 Da for a synthetic truncated form, and lists no single molecular formula because the recombinant material is a protein. The material is supplied at 99%+ purity, stored at −20°C in lyophilized form, for laboratory research use only.
Because Follistatin acts by binding, receptor-binding studies are the natural way to characterize it. The central questions are how tightly it holds each ligand, how quickly the complex forms and falls apart, and how it competes with receptors for the same ligand surface.
Why are receptor binding studies the core method for Follistatin research?
Follistatin does not signal and does not turn over substrate. Its activity is the formation of a ligand complex, so the properties that define it are binding properties: affinity, association rate, dissociation rate, stoichiometry, and selectivity across ligands. Cell-based readouts describe the downstream consequence of that binding, but they are one step removed from it. A binding study measures the interaction itself.
This matters for interpretation. A reporter-gene result that shows reduced SMAD-dependent signaling cannot by itself say whether the effect came from a very tight, slowly dissociating complex or from a weaker complex present at a high concentration. Binding kinetics separate those cases. Published structural and biophysical analyses of Follistatin have therefore been used to anchor the interpretation of cell-based work, and the two approaches are generally read together.
How is Follistatin's binding affinity measured?
The most common label-free approach is surface plasmon resonance. One partner, either Follistatin or the ligand, is immobilized on a sensor surface and the other is flowed across it at a series of concentrations. The resulting sensorgrams yield an association rate and a dissociation rate, and the ratio of the two gives an equilibrium dissociation constant. Published work on Follistatin and activin has described very slow dissociation, which is consistent with the near-irreversible character often attributed to ligand traps in this family.
Isothermal titration calorimetry offers a complementary view. It measures heat exchange during titration and reports affinity, stoichiometry, and the thermodynamic contributions to binding in a single experiment, without immobilization. Because Follistatin is a glycoprotein of substantial size, researchers also consider whether surface immobilization alters accessible binding surfaces, and a calorimetric measurement in free solution is one way to cross-check an SPR result. Bio-layer interferometry sits between the two in practice and is used when sample consumption or throughput is the constraint.
What does a competition format add?
Direct binding tells how Follistatin engages a ligand in isolation. Competition formats ask a more biologically relevant question: what happens when Follistatin and a receptor both want the same ligand. In a typical design, an activin or GDF-8 ligand is captured on a surface, a receptor ectodomain is bound to it, and Follistatin is introduced to see whether it displaces the receptor or blocks receptor engagement in the first place.
Published structural analyses indicate that Follistatin wraps around the ligand and occludes both the type I and type II receptor binding epitopes, which explains why competition experiments typically show strong blocking rather than partial interference. Comparing the apparent inhibition constant from a competition assay with the direct dissociation constant from an SPR run is a standard consistency check, and disagreement between the two points to something worth examining in the assay design, such as ligand heterogeneity or partial occupancy of the immobilized surface.
How selective is Follistatin across TGF-β family ligands?
Selectivity is a recurring theme in the literature. Follistatin binds activin A and GDF-8 with high reported affinity, while its interactions with BMP family members such as BMP-4 and BMP-7 are generally described as weaker. A binding-panel format makes this directly comparable: the same Follistatin preparation is tested against each ligand on the same platform, so differences in the measured constants reflect the ligands rather than differences in assay conditions between laboratories.
This approach is also how related ligand traps are ranked against one another. When two binding proteins show overlapping but non-identical profiles across the family, a side-by-side kinetic comparison is the cleanest way to describe the difference. For Follistatin, the practical value of the panel is that it defines the boundaries of the interaction, so that signaling results in a cell model can be read against a known binding profile.
How do isoforms and heparan sulfate binding affect the picture?
Follistatin exists as isoforms that differ in their C-terminal region, and the isoform with the acidic tail binds cell-surface heparan sulfate proteoglycans less avidly than the isoform without it. In a purified-component binding assay this difference may be invisible, because there are no proteoglycans present. In a format that includes heparin or heparan sulfate, immobilized or in solution, the isoform difference becomes measurable as an altered apparent affinity or retention.
This is one reason researchers specify the form in use. The catalog distinguishes the recombinant material from the truncated synthetic form, and a binding constant measured with one cannot be assumed for the other. Reporting the form, the construct boundaries, and the glycosylation state alongside any measured constants is what makes a binding result reproducible in another laboratory.
What practical variables affect reproducibility in these assays?
Several variables recur. Protein quality comes first: as a glycoprotein, Follistatin is more sensitive to handling stress than a short synthetic peptide, and aggregation or partial unfolding can distort kinetic fits by introducing heterogeneous binding. Surface density in SPR matters too, since high ligand density on the sensor produces mass-transport and rebinding artifacts that make dissociation appear slower than it is. Buffer composition, ionic strength, and temperature all shift measured constants and should be fixed and reported.
Model choice also deserves care. A simple one-to-one binding model is often the starting point, but a bivalent or two-state model may fit better when the ligand is a dimer, as activin and GDF-8 are. Reporting the model, the fit residuals, and the range of concentrations tested allows others to judge how much weight a reported constant can bear. This article does not provide preparation or handling instructions; those are determined by the researcher according to experimental design and applicable institutional guidelines.
How does Amino Kinetics source Follistatin for binding work?
Amino Kinetics supplies Follistatin as a research-grade compound held to a 99%+ purity specification, with analytical documentation available for every batch. Specifications, available sizes, and pricing are on the Follistatin product page, and the complete research catalog is at all compounds. For related background on domain architecture and signaling, see the Amino Kinetics articles on Follistatin and activin signaling and Follistatin in in vitro models. All material is intended for laboratory research use only.
This compound is a research chemical intended for laboratory and scientific research purposes only. It is not a drug, supplement, or food, and is not intended to diagnose, treat, cure, or prevent any disease. Amino Kinetics does not sell products intended for human or animal use. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.
